Joele Frank is handling Forma Therapeutics as the Watertown, MA-based biopharmaceutical company focused on sickle cell disease and other blood disorders is acquired by Novo Nordisk for $1.1B cash.
The Danish company has developed Etavopivat, which is currently being evaluated in global trials to treat sickle cell disease.
“Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with rare and devastating diseases,” said Ludovic Helfgott, EVP and head of rare disease unit.
The addition of Forma’s ‘differentiated approach’ to address unmet needs for patients is a step forward in enhancing our sickle cell disease pipeline.” added Helftogg.
Joele Frank, Wilkinson Brimmer Katcher’s Jamie Moser and Greg Klassen represent Forma Therapeutics.